Picture of Ludwig Enterprises logo

LUDG Ludwig Enterprises Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly Speculative

Momentum

Relative Strength (%)
1m-42.37%
3m-22.17%
6m-56.39%
1yr-78.48%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-74.76%
50d MA-31.82%
200d MA-60.87%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS  /

Blurred out image of Ludwig Enterprises EPS forecast chart

Profile Summary

Ludwig Enterprises, Inc. is a technology and health related company that is developing products that use mRNA-based genetic markers with the potential to measure the presence of inflammation, and, as a result, inflammatory-driven diseases and monitor patient response to treatment. Its proprietary mRNA genomic technology has the potential of screening for genetic biomarkers for inflammatory-driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID. The Company employs a non-invasive cheek swab test to collect mRNA samples. Its initial product candidate is the Revealia Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA expression associated with the presence of breast cancer. Its technology platform integrates three key components: non-invasive sample collection, genomic analysis, and machine learning-based interpretation.

Directors

    Last Annual
    Last Interim
    Incorporated
    February 8th, 2006
    Public Since
    December 11th, 2007
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq

    LUDG Share Price Performance

    Upcoming Events for LUDG

    Similar to LUDG

    Picture of 4Cable TV International logo

    4Cable TV International

    us flag iconPink Sheets on Nasdaq

    Picture of Abattis Bioceuticals logo

    Abattis Bioceuticals

    us flag iconPink Sheets on Nasdaq

    Picture of Accelera Innovations logo

    Accelera Innovations

    us flag iconPink Sheets on Nasdaq

    Picture of Quantum Medical Transport logo

    Quantum Medical Transport

    us flag iconPink Sheets on Nasdaq

    FAQ